Formulation Development
GRI Bio Showcases GRI-0621’s Potential to Reduce Inflammation, Type 1 Cytokines & Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis
GRI Bio, Inc. recently announced the presentation of positive preclinical data demonstrating its lead program GRI-0621 reduces important inflammatory and fibrotic drivers in Idiopathic Pulmonary…
Eradivir’s Therapeutic Proven to Reduce Advanced-Stage Influenza Viral Loads Faster, More Thoroughly in Preclinical Studies Than Current Therapies
Eradivir has developed a patent-pending antiviral therapeutic that reduces lung viral loads of advanced-stage influenza in preclinical studies quicker and more effectively than currently available…
Abzena Expands Analytical Capabilities to Include GMP Cell-Based Potency Testing Across US & UK Sites
Abzena recently announced the expansion of their early and late phase analytical capabilities to now include GMP cell-based potency assays at their Cambridge, UK and San…
Lonza Announces First GMP Batch Completion at Next-Generation Mammalian Manufacturing Facility in Portsmouth (US)
Lonza, a global development and manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, today announced the completion of the first GMP product batch supported…
Verge Genomics Announces Milestones in Collaboration With Lilly to Discover & Develop Novel Treatments for ALS
Verge Genomics recently announced Eli Lilly & Company has opted to pursue the development of therapeutics against two validated drug targets for amyotrophic lateral sclerosis…
Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease
Voyager Therapeutics, Inc. recently announced it has selected a lead development candidate, VY1706, for its tau silencing gene therapy program in Alzheimer’s disease. The company…
ImmuneSensor Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designations for Aicardi Goutières Syndrome Treatment
ImmuneSensor Therapeutics recently announced the US FDA has granted both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) for the company’s lead anti-inflammatory…
Genezen Appoints New Chief Operations Officer
Genezen recently announced the appointment of Mike Wourms as Chief Operations Officer. This appointment bolsters Genezen’s strategic growth plan and comes at a time of…
PCI Pharma Services & ChiRhoClin Partner to Prevent Shortage of Critical Orphan Pancreatic Drug
PCI Pharma Services (PCI) is collaborating with theranostics specialist ChiRhoClin, Inc. to avoid the potential shortage of a critical diagnostic drug used to test for…
Theolytics Doses First Patient in Phase 1/2a Trial of THEO-260 in Ovarian Cancer
Theolytics has dosed the first patient in its Phase 1/2a multi-centre, open-label first-in-human trial (OCTOPOD - NCT06618235) of THEO-260 in patients with advanced-stage platinum-resistant ovarian…
Ardena’s New State-of-the-Art Nanomedicine Facility Secures Full GMP Approval for Manufacturing
Ardena recently announces the full Good Manufacturing Practice (GMP) approval of its expanded nanomedicine facility in Oss. Granted by the Dutch Healthcare Authority, the approval enables…
Biolojic Design Joins Johnson & Johnson Innovation - JLABS
Biolojic Design recently announced it is joining the Johnson & Johnson Innovation – JLABS (JLABS) site in Washington, D.C. As part of JLABS @ Washington,…
Gattefossé Announces Inauguration of its New Premises & Technical Center of Excellence in Mumbai
India is a strategic country for the business development of the Gattefossé Group. To support this growing market, Gattefossé continues to invest in the opening…
Steritas Announces Collaboration With argenx to Advance Evidence for Novel Steroid-Sparing Therapeutics
Steritas LLC recently announced a licensing agreement with argenx, a global immunology company, for use of its STOX Suite of steroid-toxicity clinical outcome assessments (COAs)…
GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients With Chronic Lymphocytic Leukemia
GeoVax Labs, Inc. recently announced the completion of an interim data review by the Data Safety Monitoring Board (DSMB) for the ongoing Phase 2 clinical…
HCW Biologics & WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate
HCW Biologics Inc. and WY Biotech Co., Ltd. recently announced they have entered into a worldwide exclusive license agreement to develop and commercialize one of…
Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy
Trogenix Ltd emerged from stealth mode to unveil its groundbreaking therapeutic platform for treating aggressive cancers. Built from inception by 4BIO Capital, which specializes in…
MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
MBX Biosciences, Inc. recently announced the completion of the last subject’s last visit in its Phase 1 single and multiple ascending dose trial of MBX…
EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 IBS
EnteroBiotix Limited recently announced the completion of recruitment in its Phase 2 TrIuMPH (Treating IBS with an Intestinal Microbiota Product for Health) trial assessing the…
Bluejay Therapeutics Reports Best-in-Class Monoclonal Antibody Achieved 100% Virologic Response & Up To 78% Combined Virologic Response, & ALT Normalization as Monotherapy in Participants With Chronic Hepatitis D
Bluejay Therapeutics recently announced new data from its Phase 2 study of BJT-778, a best-in-class investigational, fully human, high-affinity monoclonal antibody (mAb) that targets hepatitis…
